南京微创医学科技股份有限公司地址（南京微创医学）

今天给各位分享南京微创医学的知识，其中也会对南京微创医学科技股份有限公司地址进行解释，如果能碰巧解决你现在面临的问题，别忘了关注本站，现在开始吧！

本文目录一览：

• 1、请大家帮忙翻译这段话 谢谢
• 2、南京市第一医院的特色科室
• 3、南京微创医学科技有限公司 怎么样
• 4、南京微创医学科技股份有限公司怎么样？
• 5、南京的医疗水平，列举南京什么医院看什么病厉害？分别说南京人民医院、南京鼓楼医院、南京军区总院

请大家帮忙翻译这段话 谢谢

Introduced on behalf of the enterprise

I, on behalf of the enterprise-based R D outsourcing

Nanjing Chuanbo Biotechnology Co., Ltd. in August 2003 incorporated in the high-tech zones, with a registered capital of 12,000,000 yuan, is a Ph.D. from abroad and domestic scientists co-founder of the biotechnology business. Chuanbo to have a biological foreign experts and overseas students as the main body and doctorate or master's degrees composition of the technical backbone of the team. The company is committed to research and development of anti-antibody protein phosphorylation, after 3 years of research and development, has succeeded in building a development of the anti-protein phosphorylation antibody technology platform, has developed 17 kinds of cell signaling pathway in the 638 kinds of anti-phosphorylation Protein antibodies, 73 of which for the first time on the international success of the development of the antibody products, products have been sold in the United States, Canada, Britain, France, Germany and Japan more than 20 countries. Annual output value reached 125 million. Science and Technology Development Zone Company and established a joint venture center "of the Nanjing International Antibody Engineering Research Center," the company for long-term development strategy that antibody drug research platform for international cooperation.

Second, the production of medical equipment on behalf of the enterprise

Minimally invasive Nanjing Medical Technology Co., Ltd. specializes in interventional stent lumen, a one-time sterile digestive endoscope, and so on endoscopic biopsy forceps the annex to the research and development of products and production sales. Own more than 10 patents, the Ministry of Health is "100 10-year plan to" bear the unit, China is the birthplace of the one-time biopsy forceps. The company has 1500 in line with the GMP requirements of 10,000 square meters clean workshop, is currently the only shop in the clean production of the stent business. Company sales in 2007 amounted to 100,000,000 yuan.

Third, medicine, health products on behalf of the production-oriented enterprises

Kang Hae Medicine Co., Ltd. Nanjing (formerly Nanking Zhenzhong Biological Engineering Co., Ltd.), the main product is Lentinan Nanjing in a row to support the eight years of their own intellectual property rights of high-tech products. The products have more than 80% of the domestic market, with an annual output capacity of 650,000, the output value reached 80,000,000 yuan. The other two companies - taxol liposomes and selegiline hydrochloride in the next two years will create a production value of 50,000,000 yuan. The company is "Lentinan freeze-dried powder", "amifostine injection", "paclitaxel liposome components" has been an international PCT patent applications and has the United States, Japan, Russia, India, Thailand, the European Union Multi-national patent applications.

High-tech Zone of bioengineering and medicine industry with the times, the industry continues to prosper and grow in 2010 and bio-medical engineering science and technology park planning area will be 5.2 square kilometers, 200 enterprises to join in annual sales 20,000,000,000 yuan . Chinese medicine and bio-technology park for a leading innovation-driven, and increase input in research funding, to foster a number of market competitiveness and self-development capacity of the backbone of the new entity; at the same time establish and improve the research and development, pilot production technology platform. With mice research advantage of the resources of the library resources, biological targeting information technology, biomedical engineering, gene therapy technology to carry out industrialization of research work, at home and abroad to introduce genetic engineering-related fields of research and development institutions to further biomedical park in Nanjing to play the "three drug "Model Base of new drugs and the role of R D base, to build a unique national biomedical research base.

Focus on the future development of the field

① biological information technology, bio-chip technology, biomedical engineering, gene therapy, cell therapy, such as the industrialization of research. Focus on the development of bio-informatics research and development platform, biological diagnostic chips, cellular immune therapy drugs, monoclonal antibody diagnostic reagents, genetic engineering drugs and vaccines and other products.

② Chinese medicine and natural medicine quality standard certification technology; ingredient extraction, separation, purification, micro technology; active ingredients of Chinese medicine screening, the study of lead compounds, controlled-release technology of proprietary Chinese medicines, transdermal absorption of technology and targeted drug delivery technology And the development of Chinese medicine capsules, effervescent tablets, injections, pills, tablets, oral solution, and other new agents.

③ priority to the development of pharmaceutical chemical release, controlled release, targeted drug delivery technology and other modern technology. For cardiovascular disease, cancer, diabetes, autoimmune disease, kidney disease and hepatitis, multiple illnesses, development, with the introduction of advanced technology at home and abroad of new drugs.

南京市第一医院的特色科室

南京市第一医院心胸外科是江苏省医学重点学科、江苏省临床重点专科、南京市医学重点专科、南京医科大学外科学（胸心外）博士培养点；是卫生部批准的首批心脏移植中心和胸腔镜培训基地。现有高级专业技术职称人员13名，硕、博士24名，床位72张。80年代开展体外循环心脏直视手术，90年代以来与美国奥卡拉心脏研究所和克里夫兰心脏中心建立了长期广泛的技术交流与合作。

目前常规开展各种先天性心脏病的矫治手术、各种心脏瓣膜置换和成型手术；在微创心脏搭桥、心脏移植、主动脉瘤和主动脉夹层的急症手术(全弓置换+支架象鼻)、重症心脏多瓣膜手术、梗阻性肥厚性心肌病手术、迷宫手术治疗房颤、ECMO心肺支持等方面更具专科特色，自2007以来每年心血管手术量已超过1000例；完成18例心脏移植手术，首例心脏移植病人已正常存活9年。完成各类心脏搭桥3000余例，成功率达98%以上，能完成卫生部所规定的三甲医院所要求的所有甲、乙类手术。 南京市第一医院心血管内科为国家级重点学科、江苏省医学重点学科、南京医科大学重点学科、南京市临床重点专科、首批卫生部冠心病介入诊疗培训基地、国家级药物临床试验基地、江苏省心血管药物临床试验服务中心，硕博士培养点。科室现有高级专业技术职称人员15名，硕、博士生导师9名，硕、博士32名，床位162张。

该科设有三个心血管介入病区：一个CCU、一个心脏分子生物学研究室、一个冠状动脉影像研究室及三个国际先进的心脏导管中心。有齐全的心血管无创伤性检查室（包括心电图，动态心电图，动态血压，负荷心电图研究室）。导管室包含冠状动脉内超声，心脏电机械标测导航系统，冠状动脉内压力导丝检测系统等。在多个省市建立28个冠脉介入诊疗分中心。门诊实行专科化管理，有中高级职称医师坐诊，能完成卫生部所规定的三甲医院所要求的所有甲、乙类手术。

南京市第一医院皮肤性病科成立于1953年，是南京医科大学附属南京第一医院成立较早的科室之一，属二级临床学科，目前仅开设门诊(本部、南院及鑫园)，具备较强的专科特色。

1、目前开设的诊室有：专家门诊、普通门诊(3个)、性病专科门诊、美容门诊、南院门诊、鑫园门诊;

2、治疗室有：性病治疗室;一般治疗室：本部、南院、鑫园)均有，主要治疗项目有：冷冻、微波、频谱、冷喷等;临床实验室(真菌等)。

3、人员结构：有医护人员8人，其中主任医师1人，副主任医师2人，主治医师1人，住院医师3人，主管护师1人。拥有博士1人，硕士1人。

4、门诊工作量及病人来源：科室每年门诊量约为5.6万人次。 每年以8%左右的速度递增。主要收治城南地区、部分郊县及邻近省市的大量皮肤病、性病患者。

5、承担南医大及省职医大的理论教学，承担各医学院校的实习带教及进修生的带教。 男，主任医师，教授，硕士生导师，1998年调入南京市第一医院心内科工作至今，全心全意服务于患者，努力引进、应用、研究新技术。1998年在江苏省及国内率先开展急性心肌梗塞的急诊介入治疗，组建了国内多中心，成果获江苏省科技进步二等奖。同年积极引进二项冠心病介入治疗的新技术??经皮切割球囊成形术与冠状动脉内超声，其研究成果分别获江苏省科技进步三等奖及省卫生厅新技术引进二等奖。1999年开展了静脉包被支架的实验及临床研究，论文发表在中国循环杂志（2000年9月）。并陆续在国内和省内开展了如下几项最新介入治疗技术：先心病介入治疗，肥厚性心肌病化学消蚀术，急性夹层动脉瘤及胸腹主动脉病的介入治疗。

南京微创医学科技有限公司 怎么样

别去，里面管理差的一塌糊涂，每月都不按时发工资，你想想看这种企业能去嘛。

南京微创医学科技股份有限公司怎么样？

南京微创医学科技股份有限公司是2000-05-10在江苏省南京市注册成立的股份有限公司(中外合资、未上市)，注册地址位于南京高新开发区高科三路10号。

南京微创医学科技股份有限公司的统一社会信用代码/注册号是913201006089812733，企业法人隆晓辉，目前企业处于开业状态。

南京微创医学科技股份有限公司的经营范围是：医疗器械的研发、生产与销售（凭许可证所列事项生产经营）；与本企业业务相关的产品及技术的进出口业务（不涉及国营贸易管理商品，涉及配额、许可证管理商品的，按国家有关规定办理申请）；消毒灭菌服务；企业管理咨询服务；自有房屋及设备租赁。（依法须经批准的项目，经相关部门批准后方可开展经营活动）。本省范围内，当前企业的注册资本属于一般。

南京微创医学科技股份有限公司对外投资5家公司，具有0处分支机构。

通过百度企业信用查看南京微创医学科技股份有限公司更多信息和资讯。

南京的医疗水平，列举南京什么医院看什么病厉害？分别说南京人民医院、南京鼓楼医院、南京军区总院

到百度上搜“复旦版最佳医院排行榜”你就能看到医院排名以及每个医院科室的全国排名。

南京微创医学的介绍就聊到这里吧，感谢你花时间阅读本站内容，更多关于南京微创医学科技股份有限公司地址、南京微创医学的信息别忘了在本站进行查找喔。